Ablative and non-ablative laser resurfacing treatments differ significantly in their approach and outcomes. Ablative lasers remove tissue to promote healing, while non-ablative lasers create thermal zones without damaging the surface.
Fractional laser resurfacing treats the skin in a pattern of microscopic treatment zones while leaving surrounding tissue untreated. This approach allows for recovery in untouched areas, which is the principle behind fractional treatments.
A 1540 nm Er:Glass system is used for non-ablative fractional treatments, while a 2940 nm Er:YAG system is for ablative fractional resurfacing. The 2940 nm wavelength removes microscopic columns of tissue, whereas the 1540 nm wavelength creates thermal coagulation zones beneath the skin's surface.
| Planning Question | 1540 nm Er:Glass | 2940 nm Er:YAG |
|---|---|---|
| General Category | Non-ablative fractional | Ablative or fractional ablative |
| Primary Tissue Effect | Controlled dermal thermal zones with surface largely intact | Controlled removal of microscopic tissue columns with a surface wound-healing response |
| Typical Planning Priority | Remodeling with a lighter recovery profile | More direct surface renewal and textural correction with greater recovery demands |
| Downtime | Often lower, but dependent on settings and patient response | Often higher, but dependent on depth, density, coverage, and protocol |
| Key Risk Questions | Heat accumulation, pigment response, endpoint consistency | Barrier disruption, wound care, infection, erythema, pigment change, healing |
A non-ablative fractional option is suitable for dermal remodeling with minimal surface disruption and a lighter recovery window. It is effective for texture improvement, selected scars, and fine lines when patients are not candidates for more aggressive treatments.
An ablative fractional treatment is appropriate for texture or resurfacing goals when the patient can manage the recovery. It requires careful screening, endpoint control, and aftercare to ensure safety and effectiveness.
No, combination treatments can target different tissue areas, but evidence from one device or wavelength cannot be generalized to another. Each hybrid protocol must be validated as a complete system.
The treatment sequence and intensity should be based on the treatment goal, patient assessment, device labeling, and manufacturer training. A disciplined approach may involve using one modality followed by reassessment.
A resurfacing platform must function as a cohesive clinical system. Clinics should assess training consistency, patient selection, downtime management, and post-treatment support.
An ablative fractional laser removes microscopic columns of tissue and creates a surface wound-healing response, while a non-ablative fractional laser creates controlled thermal zones beneath a largely intact surface.
A 1540 nm Er:Glass fractional laser is generally categorized as non-ablative, creating controlled thermal zones without removing the surface like a 2940 nm Er:YAG treatment.
Only if the exact device protocol, patient assessment, labeling, training, and qualified clinician support that sequence. Evidence from another hybrid platform cannot be assumed to validate a ZELUSSO combination.
XOD describes Zelux as a fractional non-ablative 1540 nm Er:Glass module and Erbiance as a fractional ablative 2940 nm Er:YAG module. Clinics should review the indications, protocols, recovery guidance, and training for each module before offering treatment.
An ablative fractional laser removes microscopic columns of tissue and creates a surface wound-healing response, while a non-ablative fractional laser creates controlled thermal zones beneath a largely intact surface.
A 1540 nm Er:Glass fractional laser is generally categorized as non-ablative, creating controlled thermal zones without removing the surface like a 2940 nm Er:YAG treatment.
Only if the exact device protocol, patient assessment, labeling, training, and qualified clinician support that sequence. Evidence from another hybrid platform cannot be assumed to validate a ZELUSSO combination.
XOD describes Zelux as a fractional non-ablative 1540 nm Er:Glass module and Erbiance as a fractional ablative 2940 nm Er:YAG module. Clinics should review the indications, protocols, recovery guidance, and training for each module before offering treatment.
The phone number for XOD is (617)-599-6621.